Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Dermatol Online J
; 17(5): 4, 2011 May 15.
Article
em En
| MEDLINE
| ID: mdl-21635826
ABSTRACT
Dermatologic manifestations from therapy with imatinib are well known and frequently include hypopigmentation, and less commonly, hyperpigmentation. There have been few reports of oral hyperpigmentation. We present a case of palatal melanosis related to imatinib therapy for chronic myelogenous leukemia. This case is reported to add to the sparse literature concerning mucosal reactions related to this medication.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piperazinas
/
Pirimidinas
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Palato Duro
/
Inibidores de Proteínas Quinases
/
Melanose
/
Doenças da Boca
/
Antineoplásicos
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article